Effects of precision health management combined with dual-energy bone densitometer treatment on bone biomarkers in senile osteoporosis patients

Abstract

Objective

This study investigates the effects of precision health management combined with dual-energy X-ray absorptiometry (DXA) therapy on bone biomarkers in elderly osteoporotic patients.

Methods

236 elderly patients diagnosed with osteoporosis between May 2020 and November 2021 were enrolled from our hospital. Patients were randomly allocated to either the observation group (n = 118), receiving precision health management alongside DXA therapy, or the control group (n = 118), receiving standard treatment. Clinical data were compared between the two groups. Protein levels of bone formation markers (BSAP, OC) and bone resorption markers (CTX, DPD, TRAP) were analyzed using Western blotting. Bone mineral density (BMD) was measured using DXA at baseline, 12 months, and 24 months. Pain levels were assessed using the Visual Analog Scale (VAS) at the same intervals. Osteoporosis knowledge and self-management confidence were evaluated using respective scales before and after intervention.

Results

Baseline characteristics did not significantly differ between groups (P > 0.05). The observation group exhibited decreased BSAP and increased OC and OC protein expressions compared to the control group (P < 0.05). CTX, DPD, and TRAP protein levels were significantly lower in the observation group (P < 0.05). Prior to the intervention, there were no significant variations observed in BMD, as well as VAS, knowledge, and self-efficacy scores between the two groups (P > 0.05). However, over the course of 12 and 24 months, the observation group exhibited significant increases in BMD (P < 0.05). VAS scores were notably lower in the observation group during both follow-up assessments (P < 0.05). Furthermore, knowledge scores were higher in the observation group at 12 and 24 months (P < 0.05), while self-efficacy scores showed significant improvement in the observation group at both follow-up intervals (P < 0.05).

Conclusion

Precision health management combined with DXA therapy positively impacts elderly osteoporotic patients by enhancing bone biomarkers, promoting bone growth, and preventing bone loss. This approach leads to increased BMD, reduced fracture risk, improved pain management, and enhanced knowledge and self-management abilities related to osteoporosis.